Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemothera

Name: Phase 3 Topline: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemothera
Start: 2028-06-30

June 30, 2028

Company: ADC Therapeutics SA (ADCT)
Drug: loncastuximab
Indication: Refractory Diffuse Large B-Cell Lymphoma; Relapsed Diffuse Large B-Cell Lymphoma

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemothera — ADCT Phase 3 Readout | BioSniper